Bernstein raised the firm’s price target on HCA Healthcare to $362 from $317 on Friday, while keeping a Market Perform rating on the shares. The firm has updated HCA’s model moving into Q2 reporting. Its new model assumes equiv. volume will grow at CAGR of 4.0% in 2023-2027, and rates growing 2.9%, leading to annual revenue growth of 7.0% during this period. Overall, Bernstein expects adjusted EBITDA will grow to $16,054M over this period.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $376 from $367 at Barclays
- HCA Healthcare price target raised to $375 from $359 at Deutsche Bank
- Augmedix says Go ED has met HCA’s criteria for expansion
- HCA business thriving, hospitals paying a price, Barron’s says
- HCA Healthcare price target raised to $332 from $327 at JPMorgan